ALGIFEN 500 mg/2 mg/0,02 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

algifen 500 mg/2 mg/0,02 mg/ml

zentiva s.a. - romania - combinatii (metamizolum natrium+pitofenoni hydrochloridum+fenpiverini bromidum) - sol. inj. - 500mg/2mg/0,02mg/ml - antispastice in asociere cu analgezice anticolinergice de sinteza in combinatii cu analgezice

ALGIFEN 500 mg/5 mg/0,1 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

algifen 500 mg/5 mg/0,1 mg

zentiva s.a. - romania - combinatii (metamizolum natrium+pitofenoni hydrochloridum+fenpiverini bromidum) - compr. - 500mg/5mg/0,1mg - antispastice in asociere cu analgezice anticolinergice de sinteza in combinatii cu analgezice

Brukinsa Uniunea Europeană - română - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - agenți antineoplazici - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Imbruvica Uniunea Europeană - română - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Agar Wilkins Chalgren (Wilkins Chalgren Anaerobic Agar) România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agar wilkins chalgren (wilkins chalgren anaerobic agar)

sc sanimed international impex srl -

Mediu Wilkins Chalgren (Wilkins Chalgren Anaerobic Agar) România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

mediu wilkins chalgren (wilkins chalgren anaerobic agar)

societatea nationala "institutul pasteur" sa -

AGAR WILKINS CHALGREEN România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agar wilkins chalgreen

sc deltarom srl -

AGAR WILKINS CHALGREN România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agar wilkins chalgren

sc medicamed market srl -

AGAR WILKINS CHALGREN + 5% SANGE DE BERBEC România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agar wilkins chalgren + 5% sange de berbec

sc medicamed market srl -

AGAR WILKINS CHALGREN +5% SANGE BERBEC România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

agar wilkins chalgren +5% sange berbec

sc deltarom srl -